ArticleCellular and molecular life sciences : CMLS2026
Tumour cell-intrinsic complement C1r and C1s regulate cancer cell fitness and shape the immune microenvironment in triple-negative breast cancer.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Emerging evidence positions tumour cell-intrinsic complement proteins as regulators of cancer cell behaviour and immune crosstalk, yet their role in triple-negative breast cancer (TNBC) remains undefined. Here, transcriptomic profiling across breast cancer molecular subtypes reveals that C1R, C1S and C3 are preferentially expressed in TNBC cells, both in patient tumours and in vitro, and that their expression is upregulated by pro-inflammatory cytokines. In situ mRNA hybridization and hyperplex SeqIF immunofluorescence demonstrate that C1R and C1S share more closely matched expression patterns with one another than with C3 within TNBC cell populations. These patterns associate with distinct transcriptional programs: metabolic and cell cycle gene sets are enriched in C1R-, C1S- and C3-high cells, whereas inflammatory and apoptotic signatures are specifically linked to C1R and C1S. Functionally, silencing of C1r or C1s modestly impairs TNBC cell proliferation, viability and tumoursphere formation — effects not rescued by extracellular protein supplementation, supporting an intracellular mechanism. C3 silencing exerts minimal effects. C1R- and C1S-high tumour cells are enriched in chemoattractant chemokines in patient tumours, and their secretion decreases upon complement gene silencing in vitro. C1R and C1S expression further correlates with cytotoxic T cell infiltration and improved patient survival. Together, these findings indicate that whilst cell-intrinsic C1r and C1s enhance modestly tumour cell fitness, their more consequential contribution lies in shaping the tumour immune microenvironment through regulation of chemokine secretion and cytotoxic T cell infiltration, highlighting their role as enhancers of anti-tumour immunity in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.